FOXO TECHNOLOGIES INC. (FOXO) Form 10-Q — May 15, 2026
FOXO Technologies reported a net loss of $1.5 million for the three months ended March 31, 2026, driven by operating losses and significant interest expense on its debt portfolio. Revenue increased 63% year-over-year to $5.2 million, primarily due to the inclusion of its newly acquired subsidiary, Vector BioSource, but this growth was insufficient to offset the company's heavy debt burden and operational costs. The filing includes a critical going-concern warning, stating there is substantial doubt about the company's ability to continue as a going concern.
Key figures
- Revenue
- 5168036
- Total Debt
- 36150020
- Revenue Yoy
- +63%
- Cash Position
- 65896
- Shares Outstanding
- 3732660151
- Reverse Split Ratios
- ["1:10","1:1.99"]
Price after filing
Close on the filing date to close N calendar days later (from $0.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.